In this interactive, CME/CE-certified module, Shaji Kumar, MD, provides expert perspective on advances in diagnosis and initial treatment of patients with multiple myeloma.
In this interactive, CME-certified module, Sagar Lonial, MD, provides expert perspective on advances in the treatment of patients with relapsed/refractory multiple myeloma.
Carol Ann Huff, MD, presents optimal treatment strategies for patients with newly diagnosed myeloma, including diagnosis, induction therapy, maintenance therapy, and management of particularly challenging cases.
In this downloadable slideset, Carol Ann Huff, MD, discusses the most recent data for newly diagnosed myeloma, including diagnosis, induction therapy, maintenance therapy, and management of particularly challenging clinical scenarios.
In this CME-certified module, Jacob P. Laubach, MD, MPP, discusses current therapeutic approaches for 5 challenging relapsed/refractory myeloma patient cases. The activity includes recommendations from myeloma experts and review of data supporting optimal treatment choices in this setting.
In this downloadable slideset, Jacob P. Laubach, MD, MPP, discusses the most current data and expert recommendations for treatment of patients with relapsed/refractory myeloma, focusing on case-based management of particularly challenging clinical scenarios.
Anti-CD38 antibodies like daratumumab can cause false-positive results on blood tests in myeloma. Do you know how to mitigate this risk?
With many different treatment options available for patients with R/R MM, choosing the best one can be difficult. Here is how I choose treatment for elderly patients with R/R MM.
Multiple practice-changing myeloma studies were presented at ASH this year. In this commentary, I discuss several key findings clinicians should be aware of.
With many recent changes in treatment options for relapsed/refractory MM, it can be hard to keep up. In this commentary, I review some of the most important new approaches for patients with relapsed/refractory MM.
Lenalidomide is now the first agent approved as maintenance therapy in myeloma after ASCT, but questions remain regarding its optimal use and identification of patients who will benefit the most.
With multiple recent approvals, many options exist for treating patients with myeloma. However, selecting therapy for patients relapsing after exposure to multiple therapies remains a challenge.
In this downloadable slideset, Shaji Kumar, MD, explores current thinking, best practices, and new findings that are improving treatment of patients with multiple myeloma.
Shaji Kumar, MD, explores current thinking, best practices, and new findings that are improving treatment of patients with multiple myeloma.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.